Clinical Trials

50 enrolled 10 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04439331 2026-04-13

Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U)

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04439357 2026-04-13

Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)

4 enrolled 10 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT05490771 2026-04-13

Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)

Lymphoma, Multiple Myeloma

NCT06303167 2026-04-13

Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)

19 enrolled 10 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT06308822 2026-04-13

Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1)

35 enrolled 9 charts

Lymphoma, Multiple Myeloma

NCT06400238 2026-04-13

Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H)

Lymphoma, Multiple Myeloma

NCT06400251 2026-04-13

Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol Z1K)

Lymphoma, Multiple Myeloma

NCT06385483 2026-04-07

Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)

19 enrolled 10 charts

Lymphoma, Multiple Myeloma

NCT06390826 2026-04-07

Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)

10 enrolled 10 charts

Lymphoma, Multiple Myeloma

NCT06360575 2026-03-20

Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2)

20 enrolled 10 charts

Lymphoma, Multiple Myeloma

NCT06357975 2026-03-19

Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1)

44 enrolled 10 charts

Lymphoma, Multiple Myeloma

NCT01572480 2026-03-10

Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma

55 enrolled 17 charts

Phase 3 Active not recruiting

Multiple Myeloma

NCT00602641 2026-03-03

Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

306 enrolled 12 charts

Phase 1 Active not recruiting

Multiple Myeloma

NCT03602612 2026-02-25

T Cells Expressing a Novel Fully-Human Anti-BCMA CAR for Treating Multiple Myeloma

35 enrolled 20 charts

Multiple Myeloma

NCT03031730 2026-02-10

Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma

Phase 1 Terminated

Multiple Myeloma, Plasmacytoma

NCT01237054 2026-02-06

Imaging in MGUS, SMM and MM

31 enrolled 13 charts

Phase 3 Active not recruiting

Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma

NCT01169337 2025-11-25

Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma

226 enrolled 16 charts

Phase 3 Active not recruiting

Smoldering Multiple Myeloma

NCT00114101 2025-11-24

Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant

460 enrolled 11 charts

Smoldering Multiple Myeloma, Multiple Myeloma

NCT04439110 2025-11-21

Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)

38 enrolled 10 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04439149 2025-11-21

Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N)

24 enrolled 9 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04439188 2025-11-19

Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P)

35 enrolled 9 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04439266 2025-11-19

Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F)

5 enrolled 10 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04439279 2025-11-19

Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R)

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04439344 2025-11-19

Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A)

53 enrolled 10 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04439123 2025-11-18

Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04439175 2025-11-18

Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)

70 enrolled 9 charts

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT02356159 2025-09-30

Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

Phase 1/2 Completed

34 enrolled 18 charts

Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes

NCT04439253 2025-09-18

Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G)

4 enrolled 10 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04439136 2025-09-05

Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B)

40 enrolled 10 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT03770260 2025-06-19

Ixazomib and Pevonedistat in Treating Patients With Multiple Myeloma That Has Come Back or Does Not Respond to Treatment

Phase 1 Completed

8 enrolled 11 charts

Multiple Myeloma

NCT03941860 2025-05-23

Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial

1 enrolled 1 chart

Multiple Myeloma

NCT04847050 2024-08-27

A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy

19 enrolled 18 charts

Leukemia, Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT02728102 2024-05-07

Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)

203 enrolled 25 charts

Hematologic Diseases, Multiple Myeloma

NCT02440464 2023-01-04

Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)

57 enrolled 22 charts

Hematologic Diseases, Multiple Myeloma

NCT01989598 2022-03-02

Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma

25 enrolled 11 charts

Multiple Myeloma

NCT01078454 2022-02-01

Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis

11 enrolled 6 charts

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT01109004 2021-12-09

BMT CTN 0702

758 enrolled 21 charts

Hematologic Diseases, Multiple Myeloma, Disease Progression

NCT00075829 2021-11-01

BMT CTN 0102

710 enrolled 19 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00051311 2021-09-09

Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers

62 enrolled 15 charts

Hodgkin Disease, Leukemia, Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT03958656 2021-09-09

T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma

Phase 1 Completed

13 enrolled 15 charts

Multiple Myeloma

NCT04439240 2021-06-29

Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W)

52 enrolled 10 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT03910439 2021-05-12

Avelumab in Combination With Hypofractionated Radiotherapy in Patients With Relapsed Refractory Multiple Myeloma

Phase 2 Terminated

4 enrolled 12 charts

Multiple Myeloma

NCT04439214 2021-04-06

Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D)

47 enrolled 10 charts

Turcot syndrome, Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT01402284 2021-03-02

Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients

45 enrolled 15 charts

Multiple Myeloma

NCT00437034 2021-02-08

Aflibercept for Relapsed Multiple Myeloma

Phase 2 Terminated

6 enrolled 5 charts

Multiple Myeloma

NCT02322320 2020-05-11

Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN 07LT)

273 enrolled 16 charts

DermatologicLymphoidOther hematologic neoplasmPlasma cell

Hematologic Diseases, Multiple Myeloma, Disease Progression

NCT01326702 2019-12-16

Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors

Phase 1/2 Completed

43 enrolled 18 charts

Burkitt Lymphoma, Hodgkin Disease, Immunoblastic Lymphadenopathy, Leukemia, Hairy Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Mycosis Fungoides, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, T-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Intraocular Lymphoma

NCT01239368 2019-12-10

Th1/Tc1 Immunotherapy Following Stem Cell Transplantation in Multiple Myeloma

Phase 1/2 Terminated

34 enrolled 17 charts